On this page
Neuro questions on the CCRN reward knowing sequences and thresholds: which seizure drug comes first, which number triggers ICP treatment, which finding blocks a brain death evaluation. The 12 questions below cover status epilepticus, stroke and subarachnoid hemorrhage drugs, traumatic brain injury and brain death determination.
They are written for nurses using CCRN exam prep and follow the neurological topics in the CCRN exam domains guide. Each keyed answer rests on a named guideline or FDA label, quoted in our source notes.
This set is exam practice written from the guidelines and FDA drug labels listed under References. The questions are original PrepSolution items, not AACN exam questions. It is not clinical guidance: follow your institution's protocols and the prescriber's orders. It has not been reviewed by a credentialed clinician.
Status epilepticus
Question 1: The first drug
A 45-year-old has been seizing for 6 minutes with no IV access yet. Which initial therapy does the American Epilepsy Society guideline recommend?
- A. IV fosphenytoin
- B. IV levetiracetam
- C. IM midazolam
- D. IV phenobarbital
Best answer: C. The guideline recommends a benzodiazepine, specifically IM midazolam, IV lorazepam or IV diazepam, as the initial therapy of choice. With no IV access, IM midazolam fits.
- A is not the best answer. Fosphenytoin is a second-phase option, after a benzodiazepine.
- B is not the best answer. Levetiracetam is also a second-phase option.
- D is not the best answer. The guideline calls IV phenobarbital efficacious as initial therapy but notes its slower administration rate, so it is not the initial therapy of choice, and it needs IV access.
Question 2: When the benzodiazepine fails
The patient is still seizing after an adequate benzodiazepine dose. Which statement about the second therapy matches the AES guideline?
- A. Only phenobarbital is acceptable.
- B. A second benzodiazepine infusion is the only option.
- C. Second therapy should wait 60 minutes.
- D. Reasonable options include fosphenytoin, valproic acid and levetiracetam, with no clear evidence that one is better.
Best answer: D. The guideline lists fosphenytoin, valproic acid and levetiracetam as reasonable second-phase options and states there is no clear evidence that any one is better than the others.
- A is not the best answer. The guideline does not limit the second phase to phenobarbital.
- B is not the best answer. The guideline's second-phase options are the three named drugs.
- C is not the best answer. The guideline's algorithm moves to second therapy by about the 20-minute mark, when the response to initial therapy should be apparent.
Question 3: Fosphenytoin or phenytoin
Both fosphenytoin and phenytoin are available. What does the AES guideline say about choosing between them?
- A. Phenytoin is preferred because it is faster.
- B. Fosphenytoin is preferred based on tolerability, but phenytoin is an acceptable alternative.
- C. They should be given together.
- D. Neither should be used in adults.
Best answer: B. The guideline states that when both are available, fosphenytoin is preferred over phenytoin based on tolerability, and phenytoin is an acceptable alternative (Level A).
- A is not the best answer. The guideline's preference is the other way, based on tolerability.
- C is not the best answer. The guideline does not recommend giving both together.
- D is not the best answer. Both are listed as options in adults.
Question 4: Infusing fosphenytoin
A nurse is about to give IV fosphenytoin to an adult. What does the Cerebyx boxed warning require?
- A. Keep the rate at or below 150 mg PE per minute and monitor the heart during and after the infusion
- B. Push it as fast as possible to stop the seizure
- C. Give it only intramuscularly
- D. Mix it with dextrose to prevent precipitation
Best answer: A. The boxed warning says the IV rate should not exceed 150 mg phenytoin sodium equivalents per minute in adults because of the risk of severe hypotension and cardiac arrhythmias, and that careful cardiac monitoring is needed during and after administration.
- B is not the best answer. Rapid administration is exactly what the boxed warning is about.
- C is not the best answer. The warning concerns the IV route; it does not restrict the drug to IM use.
- D is not the best answer. The boxed warning addresses infusion rate and monitoring, not the diluent.
Stroke and subarachnoid hemorrhage
Question 5: Before alteplase
A patient arrives 70 minutes after sudden right-sided weakness and aphasia began. Before alteplase is given for acute ischemic stroke, what does the Activase label require?
- A. A lumbar puncture
- B. A normal ECG
- C. Exclusion of intracranial hemorrhage as the cause of the symptoms
- D. Waiting 3 hours to confirm the deficit persists
Best answer: C. The label directs that intracranial hemorrhage be excluded as the primary cause of stroke signs and symptoms before treatment begins, and that treatment start as soon as possible but within 3 hours of symptom onset.
- A is not the best answer. A lumbar puncture is not part of the label's pre-treatment requirement.
- B is not the best answer. An ECG is not what the label requires before treatment.
- D is not the best answer. The label says to start as soon as possible within 3 hours, not to wait.
Question 6: A contraindication in stroke
Which finding is a contraindication to alteplase for acute ischemic stroke on the Activase label?
- A. Age over 70
- B. Atrial fibrillation
- C. A blood glucose of 140 mg/dL
- D. Subarachnoid hemorrhage
Best answer: D. The label lists subarachnoid hemorrhage among the situations in which alteplase should not be given for acute ischemic stroke, along with current intracranial hemorrhage, active internal bleeding, recent intracranial surgery or serious head trauma, bleeding diathesis and current severe uncontrolled hypertension.
- A is not the best answer. Age is not on the label's list of contraindications.
- B is not the best answer. Atrial fibrillation is not on the list.
- C is not the best answer. This glucose is not a listed contraindication.
Question 7: Nimodipine route
A patient with aneurysmal subarachnoid hemorrhage is ordered nimodipine. She cannot swallow, and a colleague suggests drawing the capsule contents into a syringe and giving them through the IV. What does the nimodipine label say?
- A. Never give nimodipine intravenously or by any parenteral route; injecting capsule contents has caused deaths.
- B. That is acceptable if flushed with saline.
- C. It may be given IV at half the dose.
- D. Hold nimodipine until she can swallow.
Best answer: A. The label's boxed warning says not to administer nimodipine intravenously or by other parenteral routes, because deaths and serious adverse events, including cardiac arrest and cardiovascular collapse, have occurred when capsule contents were injected.
- B is not the best answer. Flushing does not make an IV injection acceptable. The route is prohibited.
- C is not the best answer. No IV dose is safe under the label.
- D is not the best answer. The question is about the route. The label prohibits parenteral use; it does not tell the nurse to hold therapy, and enteral alternatives are a prescriber and pharmacy decision.
Traumatic brain injury
Question 8: Treatment thresholds
A patient with severe TBI has an ICP monitor. Which pair of thresholds did SIBICC adopt from the Brain Trauma Foundation?
- A. ICP above 15 mm Hg; CPP at least 50 mm Hg
- B. ICP above 22 mm Hg; CPP at least 60 mm Hg
- C. ICP above 30 mm Hg; CPP at least 80 mm Hg
- D. ICP above 20 mm Hg; CPP at least 90 mm Hg
Best answer: B. SIBICC adopted the BTF Guidelines' initial thresholds: ICP 22 mm Hg and CPP 60 mm Hg.
- A is not the best answer. These are not the BTF thresholds SIBICC adopted.
- C is not the best answer. These are too high for ICP and CPP.
- D is not the best answer. SIBICC lists routinely raising CPP above 90 mm Hg as not recommended.
Question 9: What not to do routinely
Which intervention does SIBICC list as not recommended for patients with severe TBI managed with ICP monitoring?
- A. Routinely lowering PaCO2 below 30 mm Hg
- B. Keeping the core temperature from rising above 38 C
- C. Sedation for ventilator tolerance
- D. Maintaining CPP of at least 60 mm Hg
Best answer: A. SIBICC's list of treatments not recommended includes routinely decreasing PaCO2 below 30 mm Hg, along with routine steroids, scheduled hyperosmolar infusions, lumbar CSF drainage, furosemide and routine hypothermia below 35 C.
- B is not the best answer. SIBICC's Tier Zero targets avoiding fever, defined as a core temperature above 38 C.
- C is not the best answer. Tier Zero sedation and analgesia target comfort and ventilator tolerance.
- D is not the best answer. SIBICC uses a minimum CPP threshold of 60 mm Hg.
Question 10: Seizure prophylaxis after TBI
A patient with a severe TBI and a subdural hematoma was started on seizure prophylaxis on admission. He has had no seizures. Per the ACS TQIP TBI best practices guideline, how long should prophylaxis be considered?
- A. For 6 months
- B. Indefinitely
- C. Only until the ICP monitor is removed
- D. For 1 week only, unless another indication to continue appears
Best answer: D. The TQIP guideline lists considering anti-seizure prophylaxis for 1 week only, in the absence of an indication to continue, among expected interventions for severe TBI.
- A is not the best answer. The guideline does not call for 6 months of prophylaxis.
- B is not the best answer. Prophylaxis is time-limited, not indefinite.
- C is not the best answer. The guideline ties duration to 1 week, not to ICP monitoring.
Brain death determination
Question 11: A prerequisite for the evaluation
A patient after cardiac arrest is being considered for a brain death evaluation. His core temperature is 35.2 C and BP is 112/70 (MAP 84). What must happen before the evaluation, under the 2023 consensus guideline?
- A. Nothing; the values meet the prerequisites.
- B. Warm him to a core temperature of at least 36 C.
- C. Lower his blood pressure to an SBP under 100 mm Hg.
- D. Give a sedative to prevent movement.
Best answer: B. The guideline requires clinicians to ensure core temperature is at least 36 C before a BD/DNC evaluation, and in adults to maintain SBP of at least 100 mm Hg and MAP of at least 75 mm Hg. His blood pressure is adequate, but his temperature is not.
- A is not the best answer. His temperature is below 36 C, so he does not meet the prerequisite.
- C is not the best answer. The guideline sets a minimum SBP of 100 mm Hg, because hypotension can cause a false-positive determination.
- D is not the best answer. Sedatives can confound the neurologic examination.
Question 12: Reading the apnea test
During an apnea test in an adult without chronic CO2 retention, no respirations occur. Baseline PaCO2 was 40 mm Hg. Which final ABG is consistent with brain death under the 2023 guideline?
- A. pH 7.33, PaCO2 52 mm Hg
- B. pH 7.28, PaCO2 58 mm Hg
- C. pH 7.21, PaCO2 64 mm Hg
- D. pH 7.31, PaCO2 61 mm Hg
Best answer: C. The guideline says the apnea test is consistent with BD/DNC when no respirations occur, the arterial pH is below 7.30, and PaCO2 is at least 60 mm Hg and at least 20 mm Hg above the pre-test baseline. A pH of 7.21 and PaCO2 of 64 (24 above 40) meet all three.
- A is not the best answer. The pH is not below 7.30 and the PaCO2 is under 60.
- B is not the best answer. The pH qualifies, but a PaCO2 of 58 is under 60 and only 18 above baseline.
- D is not the best answer. The PaCO2 qualifies, but the pH of 7.31 is not below 7.30.
Where does neuro content sit on the CCRN?
The CCRN Exam Handbook groups musculoskeletal, neurological and behavioral/psychosocial topics at 18% of the Adult CCRN test plan. The neurological list includes stroke, brain death, seizure disorders, traumatic brain injury, neurovascular abnormalities, spinal cord injury, encephalopathy and neurosurgery.
Numbers from this set
| Topic | Number | Source |
|---|---|---|
| Status epilepticus timing | Initial therapy phase should conclude by about 20 minutes | AES guideline |
| Fosphenytoin IV rate, adults | Not over 150 mg PE per minute | FDA label |
| Alteplase for AIS | Start as soon as possible, within 3 hours of onset | FDA label |
| ICP treatment threshold | Above 22 mm Hg | SIBICC (BTF) |
| CPP minimum | 60 mm Hg | SIBICC (BTF) |
| Fever in TBI | Avoid core temperature above 38 C | SIBICC |
| BP without ICP monitoring | SBP at least 110 mm Hg, MAP above 80 mm Hg | ACS TQIP |
| Brain death prerequisites | Core temperature at least 36 C; SBP at least 100 and MAP at least 75 mm Hg | 2023 consensus guideline |
| Apnea test | pH below 7.30 and PaCO2 at least 60 and at least 20 above baseline | 2023 consensus guideline |
How should you use this set?
Answer each question before reading the rationale. Most neuro misses come from a threshold off by one step, such as a PaCO2 of 58 instead of 60, or a sequence out of order, such as a second-line drug before a benzodiazepine. For more practice across the test plan, see the CCRN clinical judgment questions, and for the full bank and timed exams, CCRN exam prep.
References
- [1] AACN Certification Corporation (2026). CCRN Exam Handbook, Direct Care (July 2026). AACN Certification Corporation. AACN Certification Corporation
- [2] American Epilepsy Society (2016). Evidence-Based Guideline, Treatment of Convulsive Status Epilepticus in Children and Adults. American Epilepsy Society. American Epilepsy Society
- [3] FDA label (2026). Cerebyx (fosphenytoin sodium) injection. FDA label. FDA label
- [4] FDA label (2026). Nimodipine capsules. FDA label. FDA label
- [5] FDA label (2026). Activase (alteplase). FDA label. FDA label
- [6] Seattle International Severe TBI Consensus Conference (SIBICC) (2019). A management algorithm for patients with ICP monitoring. Seattle International Severe TBI Consensus Conference (SIBICC). Seattle International Severe TBI Consensus Conference (SIBICC)
- [7] American College of Surgeons TQIP (2026). Best Practices Guidelines, The Management of Traumatic Brain Injury. American College of Surgeons TQIP. American College of Surgeons TQIP
- [8] AAN/AAP/CNS/SCCM (2023). Pediatric and Adult Brain Death/Death by Neurologic Criteria Consensus Guideline. AAN/AAP/CNS/SCCM. AAN/AAP/CNS/SCCM
Help us improve this guide
How helpful was this article?
One tap helps us understand what’s useful.
Frequently asked questions
The American Epilepsy Society names a benzodiazepine (IM midazolam, IV lorazepam or IV diazepam) as the initial therapy of choice.
SIBICC adopted the Brain Trauma Foundation thresholds: treat ICP above 22 mm Hg and keep CPP at least 60 mm Hg.
No. The FDA label warns never to give nimodipine intravenously or by any parenteral route; injecting capsule contents has caused deaths.
The 2023 consensus guideline requires a core temperature of at least 36 C.
In adults without chronic CO2 retention: no respirations, arterial pH below 7.30 and PaCO2 at least 60 mm Hg and at least 20 mm Hg above baseline.
No. They are original PrepSolution practice items written from the guidelines and FDA labels listed under References. They have not been reviewed by a credentialed clinician and are not clinical guidance.
Keep practicing for the CCRN.
Review the study tools, access options and price, or start with free practice.
Related Articles
CCRN Multisystem Practice Questions: Sepsis, Acid-Base, AKI and More
Twelve original CCRN multisystem questions on sepsis, vasopressors, DKA, anion gap, AKI, abdominal compartment syndrome, malignant hyperthermia and acetaminophen toxicity.
CCRN Cardiovascular Practice Questions: 13 With Rationales
Thirteen original CCRN cardiovascular questions on aortic dissection, atrial fibrillation, PSVT, cardiogenic shock and cardiac drugs, each keyed to a named guideline or FDA label.
PCCN Neuro Practice Questions: Stroke, Seizures, Delirium and TBI
Thirteen original PCCN neuro questions on NIH Stroke Scale scoring, alteplase and nimodipine label rules, status epilepticus, delirium and TBI, each keyed to a named source.
